For patients with diabetes and MASLD, SGLT2 inhibitors may offer metabolic and cardiovascular benefits while potentially improving liver health
Emerging next-generation options are Cagrisema, Retatrutide, and pipeline or investigational drugs such as VK2535, Amylin analogues, and mazdutide
Thymosin Beta-4 has been studied in Phase II clinical trials for corneal wound healing, where it showed a 59% reduction in corneal staining compared to placebo
The long-standing use of this drug in diabetes management has led to a lot of clinical data and trust from healthcare professionals, who often prescribe it as a go-to therapy
Always discuss ongoing use with your doctor to monitor any potential long-term risks, including effects on the pancreas or thyroid
The evidence base has grown to the point where ignoring it would be a disservice to every patient who walks through a cardiologist's office